ArticleNpj biological timing and sleep2026
Fecal melatonin as a biomarker of emerging circadian maturity and gut microbiota in infancy.
Article in Npj biological timing and sleep, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fecal melatonin as a biomarker of emerging circadian maturity and gut microbiota in infancy.Npj biological timing and sleep · 2026Article
- The gut microbiota and sleep in infants: a focus on diurnal rhythmicity patterns.Gut microbes reports · 2026Article
- Linking gut microbiota rhythmicity to circadian maturation in infants.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Melatonin plays a key role in circadian regulation, and its interaction with the gut microbiota may be critical for early-life development. Beyond its circadian function, melatonin dysregulation is implicated in inflammatory, metabolic, psychiatric, and neurological disorders. While the gastrointestinal tract produces melatonin at levels far exceeding the pineal gland, its role in gut microbiota dynamics and circadian maturation remains unclear. This observational study investigates the association between fecal melatonin levels and microbial diversity, specific bacterial taxa (ZOTUs), actimetry-based sleep metrics, and various time-dependent factors (including stool timing and intervals since the last stool, sleep, and meal) in infants at 3, 6, and 12 months of age. Key findings include: (1) fecal melatonin levels increase with age but show high inter-individual variability; (2) fecal melatonin is associated with time factors, such as stool timing and time since last stool; (3) higher fecal melatonin levels are linked with reduced gut microbial richness and diversity; (4) the number of bacterial taxa associated with fecal melatonin decline over time; (5) melatonin is associated with age-dependent shifts in both bacterial phyla and genera, notably increasing phyla Actinobacteriota and Bacteroidota, and genera Bifidobacterium, and Veillonella, while reducing the phylum Firmicutes and the genus Streptococcus; (6) fecal melatonin is linked to circadian maturation; and (7) finally, stool timing variability and fasting time affect fecal melatonin stability. These findings identify intestinal melatonin as a promising biomarker for gut microbiota development and circadian rhythm establishment. In addition, these insights highlight melatonin in infant stool as a biomarker and potential modulator bridging systems of intestinal microbiota and behavioral sleep-wake organization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.